iOnctura has dosed the first subject in the open-label Phase II OCULE-01 trial of oral roginolisib in individuals with rare eye cancer, metastatic uveal melanoma (UM). The randomised, parallel-arm ...
BioAtla is extending its runway beyond key clinical readouts in 1H 2026 by restructuring and realigning resources, which includes a workforce reduction of over 30%. The Company estimates that it will ...
22h
ASSISI, Italy (AP) — Pilgrims have been pouring into this medieval hilltop town to venerate not only two of the Catholic ...
Abimelec Arellano, a virtual artist better known as "abimelecdesign" on social media, has prepared the newest wishful ...
Planegg-Martinsried, Germany - Formycon AG (FSE: FYB, “Formycon”) today published its audited consolidated financial statements for the 2024 financial year and provided an outlook for fiscal year 2025 ...
US FDA approves Novartis’ oral Fabhalta for treatment of adults with C3 glomerulopathy: Basel Saturday, March 22, 2025, 09:00 Hrs [IST] Novartis announced that oral Fabhalta (ip ...
1d
MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs ...
Waste Oils RecycLe and Development project, proposes an innovative, circular and sustainable process to turn used vegetable ...
Spectral Medical Inc. ("Spectral" or the "Company") (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock ...
Every spring, one question starts to occupy more and more of my brain: How can I get more asparagus on the table? As soon as ...
After a very difficult childhood, professional life, and personal life, Preeti Vyas emerged with battle scars and honours, ...
We have done a great job of realizing that vision in the first 75 years of our existence. Let us hope our success will continue. MENTAL HEALTH administrators protest in Tel Aviv, calling for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback